This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $50.88 in the latest trading session, marking a +1.17% move from the prior day.
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $50.29, marking a -0.53% move from the previous day.
Moderna (MRNA) Stock Up on Vaccine Pipeline Expansion Plan
by Zacks Equity Research
Moderna (MRNA) plans to initiate clinical studies on new candidates as potential vaccine for seasonal flu, HIV and the Nipah virus.
Astrazeneca (AZN) Stock Moves -0.59%: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $50.56, marking a -0.59% move from the previous day.
4 Reasons for Bank ETFs to Win in 2021
by Sanghamitra Saha
Bank ETFs should stay strong in the coming days on the back of cheaper valuation, Fed's signal for buybacks, Democrat's control over Senate and spike in bond yields.
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
by Zacks Equity Research
Futures Down as Investors Weigh Covid-19 Cases Against Vaccines
Racing Against Time: Covid-19 vs. Vaccines
by Mark Vickery
This past Friday brought the U.S. its largest single-day amount of Covid-19 cases since the pandemic began in earnest back in March of last year: 310K in a single 24-hour period.
Pharma Stock Roundup: ABBV's Positive Skyrizi Data, AZN, PFE, RHHBY's FDA Updates
by Kinjel Shah
AbbVie's (ABBV) Skyrizi succeeds in psoriatic arthritis and Crohn's disease studies. AstraZeneca (AZN), Pfizer (PFE) and Roche (RHHBY) give FDA updates.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna and AstraZeneca
AstraZeneca (AZN) Farxiga Gets Priority Tag for Kidney Disease
by Zacks Equity Research
If approved for CKD, AstraZeneca's (AZN) Farxiga will be the first SGLT2 inhibitor approved to treat patients with CKD, with and without type II diabetes.
FDA Opposes Dilution of COVID-19 Vaccine Doses: Here's Why
by Indrajit Bandyopadhyay
The FDA is against any changes to the approved dosing regimens for Pfizer (PFE)/BioNTech (BNTX) and Moderna's (MRNA) coronavirus vaccines as demanded by some experts.
Astrazeneca (AZN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $50.70, marking a +0.36% move from the previous day.
Airlines End 2020 on a Solid Note: More Rally Awaited in 2021?
by Maharathi Basu
The availability of vaccines is likely to boost air travel in 2021. As a result, Delta (DAL), American Airlines (AAL), Southwest Airlines (LUV) and United Airlines (UAL) are likely to be aided by the uptick in passenger revenues.
Roche's (RHHBY) Immunotherapy Gets Breakthrough Therapy Status
by Zacks Equity Research
Roche's (RHHBY) tiragolumab in combination with Tecentriq wins Breakthrough Therapy designation for the first-line treatment of patients with metastatic non-small cell lung cancer.
Model N (MODN) Acquires Deloitte's Unit, To Expand in Life Sciences
by Zacks Equity Research
Model N (MODN) acquisition of Deloitte's life sciences pricing and contracting solutions business will help it expand presence in the life sciences market.
Moderna (MRNA) Raises COVID-19 Vaccine Production Target
by Zacks Equity Research
Moderna (MRNA) raises lower end of its global manufacturing target for its coronavirus vaccine by 20% for 2021. The company still aims to deliver up to one billion doses in the year.
Arcturus (ARCT) to Begin Phase II COVID-19 Vaccine Study
by Zacks Equity Research
Arcturus (ARCT) gets FDA's allowance of the IND filing to begin a phase II study on ARCT-021, its COVID-19 vaccine candidate, in the United States. Shares rise.
Tech Finishes as the Strongest Sector in 2020
by Zacks Equity Research
Tech Finishes as the Strongest Sector in 2020
Markets Pick Up in 2021 Right Where They Left Off
by Mark Vickery
The Dow is up more than 110 points, the Nasdaq +60 and the S&P 500 +15. It appears there is more appetite at the start of the year to shoot for new all-time highs in the market.
Top ETF Stories of Fourth-Quarter 2020
by Sanghamitra Saha
The year 2020 as a whole could easily be attributed to the COVID-19 outbreak.
Stock Market News for Dec 31, 2020
by Zacks Equity Research
U.S. stock markets closed modestly higher on Wednesday as investors monitored the progress of additional fiscal stimulus
AstraZeneca (AZN) COVID-19 Vaccine Gets Authorization in UK
by Zacks Equity Research
AstraZeneca's (AZN) vaccine for coronavirus receives emergency use approval in the United Kingdom, the first for it anywhere in the world.
Clovis (CLVS) Seeks Permission for Clinical Study on Novel Drug
by Zacks Equity Research
Clovis (CLVS) submits regulatory application to the FDA for initiating clinical study on its peptide-targeted radionuclide therapy, FAP-2286.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $49.90, marking a +1.05% move from the previous day.
AstraZeneca's (AZN) Lynparza Approved in Japan for 3 Cancers
by Zacks Equity Research
AstraZeneca (AZN) and partner Merck's Lynparza is approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.